# Epirium Bio

> Epirium Bio is a San Diego-based clinical-stage biopharmaceutical company developing orally available small molecules that target PGE2 signaling to restore tissue homeostasis, reduce inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor advancing toward a Phase 2b trial for sarcopenia, the age-related loss of muscle strength for which no FDA-approved therapy currently exists.

- **Founded:** 2008
- **Headquarters:** San Diego, California, United States
- **Founders:** Pam Taub, M.D. (Co-founder), Alan Maisel, M.D. (Co-founder), Francisco Villarreal, M.D., Ph.D. (Co-founder), Jonathan Taub (Co-founder, first CEO), Guillermo Ceballos, M.D. (Co-founder)
- **Team size:** Roughly 13 employees
- **Products:** MF-300, EPM-01, 15-PGDH / PGE2 platform
- **Notable:** Raised $85 million Series A in December 2019 co-led by Longitude Capital and ARCH Venture Partners, Received FDA clearance of the Investigational New Drug (IND) application for MF-300 (December 2024), Completed dosing in its first-in-human Phase 1 trial of MF-300

## Products & services

- **MF-300** — Lead candidate: a first-in-class, orally administered 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for sarcopenia (age-related muscle weakness). Completed a positive Phase 1 trial and is advancing toward a Phase 2b trial expected in the second half of 2026.
- **EPM-01** — An oral synthetic compound in early clinical development for Becker muscular dystrophy, part of the company's neuromuscular pipeline.
- **15-PGDH / PGE2 platform** — An IP-protected discovery platform of orally bioavailable small molecules targeting 15-PGDH inhibition to enhance endogenous PGE2 signaling, with preclinical programs in spinal muscular atrophy (SMA), inflammatory bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).

## Achievements

- Raised $85 million Series A in December 2019 co-led by Longitude Capital and ARCH Venture Partners
- Received FDA clearance of the Investigational New Drug (IND) application for MF-300 (December 2024)
- Completed dosing in its first-in-human Phase 1 trial of MF-300
- Announced positive Phase 1 results in healthy volunteers (September 2025) - MF-300 generally well tolerated with dose-related pharmacodynamic responses
- Held a positive Type C (End-of-Phase 1) meeting with the FDA supporting advancement of MF-300 to a Phase 2b trial in sarcopenia
- Developing a first-in-class oral 15-PGDH inhibitor in a disease area with no approved therapies

## Latest updates

- **2026-02** — Released a non-confidential corporate presentation detailing the oral 15-PGDH inhibitor platform leveraging PGE2 signaling.
- **2026-01** — Announced plans to present new MF-300 clinical and translational data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026.
- **2025-09** — Announced positive Phase 1 clinical trial results for MF-300 in healthy volunteers; doses generally well tolerated with dose-related pharmacodynamic responses.
- **2025-01** — Alex Casdin became Chief Executive Officer; Russell Cox transitioned to Executive Chairman.
- **2024-12** — FDA cleared the IND application for MF-300, enabling first-in-human clinical trials.

## Links

- Website: https://epirium.com
- LinkedIn: https://www.linkedin.com/company/epirium

---

Profile page: https://yespress.io/epirium-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-15